Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 1865 new people
  • 34 new organizations
  • 622 new photos
  • 1247 job history records for people in our database
  • 518 education records for people in our database
  • 2209 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 198 new policy reports
  • 12 new trips to our privately funded travel database
  • 921 new personal financial disclosures
  • 27459 new press releases
  • 30 new town halls

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

Prescription Drugs: Implications of Drug Labeling and Off-Label Use

  Premium   Download PDF Now (12 pages)
Report Type Reports and Testimonies
Report Date Sept. 12, 1996
Report No. T-HEHS-96-212
Subject
Summary:

Physicians use a drug "off-label" when they prescribe a Food and Drug Administration (FDA)-approved drug for treatments other than those specified on the label. GAO testified that off-label prescribing is prevalent and presents various problems for policy-makers at different times. As it stands now, the problem is that the drug industry believes that labels overly constrain its ability to promote its products. This problem can be solved either by relying on sources in addition to the label to define appropriate promotion or by improving the process for updating the label. These two options are not necessarily mutually exclusive and both have benefits and drawbacks.

« Return to search Government Accountability Office reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com